LRI Investments’s Stoke Therapeutics STOK Stock Holding History

LRI Investments’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-146	Closed	-$4.75K	–	2002
2026 Q1	$4.75K	Buy	+146	New	+$4.79K	﹤0.01%	1102

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

LRI Investments's STOK Position: Q2 2026 in Review

LRI Investments sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 146 shares — an estimated $4.75K sold.

LRI Investments first reported a position in STOK in Q1 2026 and held it in 1 quarter. The position peaked at $4.75K in Q1 2026. 63 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

LRI Investments reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
LRI Investments sold 146 Stoke Therapeutics shares in Q2 2026, an estimated $4.75K.
LRI Investments first reported a position in Stoke Therapeutics in Q1 2026 and held it in 1 quarter.
LRI Investments's Stoke Therapeutics position peaked at $4.75K in Q1 2026.
63 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.